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Mutations in the thyroid hormone receptor α 1 gene (THRA) have
recently been identified as a cause of intellectual deficit in humans.
Patients presentwith structural abnormalities includingmicroencephaly,
reduced cerebellar volume and decreased axonal density. Here, we
show that directed differentiation of THRA mutant patient-derived in-
duced pluripotent stem cells to forebrain neural progenitors is mark-
edly reduced, but mutant progenitor cells can generate deep and
upper cortical layer neurons and form functional neuronal net-
works. Quantitative lineage tracing shows that THRA mutation-
containing progenitor cells exit the cell cycle prematurely, resulting
in reduced clonal output. Using a micropatterned chip assay, we find
that spatial self-organization of mutation-containing progenitor cells
in vitro is impaired, consistent with down-regulated expression of
cell–cell adhesion genes. These results reveal that thyroid hormone
receptor α1 is required for normal neural progenitor cell proliferation
in human cerebral cortical development. They also exemplify quan-
titative approaches for studying neurodevelopmental disorders us-
ing patient-derived cells in vitro.
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The human cerebral cortex mediates higher cognitive andsensorimotor functions, with thyroid hormone (TH) deficiency
during pregnancy or the neonatal period recognized as the most
common preventable cause of intellectual disability worldwide (1).
Defects in progenitor cell proliferation, synaptogenesis, and den-
dritic arborization, neuronal migration, and cell survival have been
observed in the cerebral cortex of the progeny of hypothyroid
rodents (2–4). Aberrant behavior and cortical cytoarchitecture are
observed even following transient TH deficiency during the first
half of gestation, emphasizing the critical role of THs in early
brain development (5). However, in humans, the actions of THs
on cells of the central nervous system (CNS) remain poorly de-
fined (6). In the absence of appropriate in vitro models, it has
been difficult to study TH action in specific cells or tissues sepa-
rate from its global effects, which are likely mediated by a range of
tissues and cell types (7).
During cerebral cortex development, THs (thyroxine, T4; tri-
iodothyronine, T3) act via a nuclear receptor (TRα1) encoded by
the THRA gene, to regulate transcription of target genes in a
ligand-dependent manner (8–10). Unliganded TH receptors
(TRs) recruit a corepressor complex to inhibit target gene tran-
scription (11); hormone (T3) occupancy promotes dissociation of
the corepressor complex together with coactivator recruitment
and transcriptional activation (11, 12).
We reported the first human THRA mutation in 2012 (13),
after which approximately 29 other patients have been identified
with shared phenotypic features defining the disorder resistance
to thyroid hormone α (RTHα) (14–18). All the patients carry
heterozygous missense or truncating mutations in the ligand-
binding domain of TRα1 that disrupt its ability to bind T3,
impairing corepressor dissociation and coactivator recruitment
(13, 16). When coexpressed, mutant TRα1 inhibits the function
of its wild-type (WT) counterpart in a dominant-negative manner
(13). In addition to growth retardation and skeletal dysplasia,
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patients with RTHα exhibit mild-to-moderate intellectual dis-
ability, notably affecting nonverbal IQ and sensorimotor process-
ing, and 1 adult woman has experienced epileptic seizures that
began in infancy (16). These findings suggest a crucial role for
TRα1 in human cortical neurogenesis, consistent with previous
studies reporting a range of CNS abnormalities in mice mutant for
TRα1 (19). However, the cellular mechanisms underlying aberrant
neural development in patients with RTHα remain unknown.
Here we have delineated the neurologic and neurocognitive
phenotypes and undertaken structural (magnetic resonance im-
aging [MRI], tractography) neuroimaging and proton magnetic
resonance spectroscopy (MRS) in the first 4 RTHα patients
reported, harboring frameshift/premature stop THRA mutations
that are representative of the type of receptor defect found in
50% of the worldwide RTHα cohort (20). We directed differ-
entiation of THRA mutant patient-derived induced pluripotent
stem cells (iPSCs) to a cortical excitatory neuronal fate, using an
established in vitro system that recapitulates development from
early neuroepithelium to functional neuronal circuits (21, 22).
Based on quantitative analysis of lineage tracing data, we found
that THRA mutation-containing cortical progenitor cells are bi-
ased toward early differentiation, leading to premature neuro-
genesis and depletion of the progenitor cell pool. They also
exhibit impaired self-organization into cortical rosette-like struc-
tures in vitro. Defects in neural progenitor proliferation, cell po-
larity, and apical adhesion may thus contribute to the structural
abnormalities and to the sensorimotor and neurocognitive phe-
notypes seen in patients with RTHα.
Results
Neurologic, Neurocognitive, and Neuroimaging Abnormalities in Patients
with THRA Mutation. We assessed neurologic, neurocognitive, and
neuroimaging phenotypes in the first 4 RTHα cases reported (SI
Appendix, Table S1), all harboring mutations that disrupt the
carboxyterminal alpha helix of TRα1 (Fig. 1A). The subjects are a 9-y-
old female (E403X TRα1 mutation; referred to as P1 below), a
13-y-old female and her 49-y-old father (F397fs406X TRα1 mutation;
P2 and P3), and a 47-y-old female (A382PfsX7 TRα1 mutation;
P4). All 4 patients exhibited delayed developmental milestones (SI
Appendix, Table S2) and neurologic abnormalities, including slow
initiation of movement, ataxic gait, dysarthria, and fine and gross
motor incoordination (SI Appendix, Table S3).
Neuropsychological examinations showed significantly reduced
nonverbal IQ in all cases, with scores ranging from 2 (P1, P2, and
P3) to 3.4 (P4) SDs below the population mean (X = 100; SD, 1.5).
Furthermore, all patients showed severe impairments in motor
coordination, visual motor integration, and finger dexterity of both
the dominant and nondominant hands. P4 showed intellectual
disability affecting verbal as well as nonverbal abilities, whereas
verbal abilities were relatively preserved in P1, P2, and P3. Per-
formance on a test of visual perception was within the low average
to average range in P1-P3 (SI Appendix, Table S4).
Magnetic resonance imaging (MRI) revealed reduced cere-
bellar volumes in all 4 patients (Fig. 1B and SI Appendix, Fig.
S1), with microencephaly in the adult cases (P3 and P4), despite
their increased skull volume (macrocephaly) denoted by known
increased head circumference (P1, +3 SDs from the population
mean; P2, +4 SD; P3, +5 SD; P4, +9 SD) (Fig. 1C). Diffusion
tensor imaging (DTI) performed in P1 and P2 showed a global
increase in the mean diffusivity of water in white matter tracts,
denoting a reduction in their density (Fig. 1D). On MRS, there
was a reduced ratio of N-acetylaspartate to the creatine plus
phosphocreatine ratio in the frontal white matter and thalamus
in P2, P3, and P4, suggestive of neuronal loss or dysfunction (SI
Appendix, Table S5). These results suggest that the observed
neurocognitive and sensorimotor deficits in the patients are re-
lated to structural abnormalities in several brain regions, in-
cluding the cerebellum and cerebral cortex.
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Fig. 1. THRA mutations are associated with structural abnormalities in
the brain. (A) Structural modeling of the ligand-binding domain of TRα1
showing the position of mutations (red). The mutations in patients P4
(A382PfsX7), P2 and P3 (F397fs406X), and P1 (E403X) disrupt or truncate the
carboxyterminal alpha helix (H12; black) of the receptor, exposing a hy-
drophobic cleft that facilitates corepressor (CoR; blue) binding by unliganded
receptor (Left) and removing or changing amino acids required for T3 (cyan)
binding and coactivator (green) recruitment (Right). (B) MRI scans of patients
P1 and P2 and a control subject (female, age 10 y 8 mo) with T2-weighted
axial images (Top) and T1-weighted coronal images (Bottom), showing in-
creased CSF space (arrows) around the cerebellum and between folia,
denoting reduced cerebellar size. (C) Sagittal images fromMRI brain scans of
adult cases P3 and P4 and a control subject (female, age 52 y) showing
microencephaly. (D) Tract-based spatial statistics analysis of DTI data in pa-
tients P1 and P2. Tracts highlighted in blue signify greater mean diffusivity
(MD) of water than in controls (n = 20 age- and sex-matched subjects), and
tracts highlighted in green denote not significantly different MD compared
with controls.
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Reduced Differentiation of THRA Mutant iPSCs to Forebrain
Neuroepithelial Cells. To study the cellular developmental origin
of cortical abnormalities in THRA mutant patients, iPSC lines
were derived from P1, P2, and P4 by reprogramming with non-
integrating Sendai virus (SI Appendix, Fig. S2A) (23). THRA
mutant and control iPSCs were then differentiated to cerebral
cortex neural progenitor cells using an established protocol
based on dual SMAD inhibition (Fig. 2A) (21, 22). After 12 d of
induction, a neuroepithelial sheet was formed in control cultures,
and expression of PAX6 and FOXG1 mRNA confirmed cortical
identity (SI Appendix, Fig. S2B). Neural progenitor cells pro-
ceeded to generate neurons as described previously (22). In
control cultures, TRα1 was expressed in stem cells before cor-
tical induction, in cycling (Ki67+) progenitor cells, and in post-
mitotic (Tuj1+) neurons (Fig. 2B and SI Appendix, Fig. S2C),
confirming that the receptor is present throughout the in vitro
differentiation process.
When THRA mutation-containing iPSCs from the 3 patients
were subjected to the same differentiation protocol, cortical in-
duction was found to be reduced in efficiency. While cortical
transcription factors were also expressed in THRAmutant cultures
(SI Appendix, Fig. S2B), expression of PAX6 was highly variable
between cells (SI Appendix, Fig. S2D). At day 15, following manual
fragmentation of the neuroepithelial sheet, PAX6 expression in
THRA mutation-containing cells was decreased (Fig. 2 C and D).
PAX6 expression was mostly higher in, but not confined to, areas
with rosette-like morphology (Fig. 2D).
Altered Expression of Neural Development and Cell–Cell Adhesion
Genes during Neural Differentiation of THRA Mutant iPSCs. To in-
vestigate differences in induction efficiency in an unbiased manner,
we performed RNA sequencing of 3 independent neural induc-
tions from each THRA mutation-containing iPSC line (TRα1-
403X carrying the E403X mutation, TRα1-FS382 with the
A382PfsX7 mutation, and TRα1-FS397 with the F397fs406X mu-
tation) and 1 neural induction from each control line (H9, NAS6,
and NDC), at day 12 of cortical induction. Out of 16,773 transcripts
that were detected above negligible levels in all samples, we con-
sidered 478 transcripts whose expression differed significantly be-
tween THRA mutation-containing and control lines (false discovery
rate <0.25, independent of the sign of the fold change).
Hierarchical clustering analysis revealed that the expression
profiles of replicate inductions from each THRA mutation-
containing line clustered together, suggesting that the cortical
induction process in vitro preserves mutation-specific differences
in transcription (Fig. 3A). The differentially expressed genes
clustered into 4 distinct groups, with the largest subset repre-
senting genes whose expression is down-regulated in THRA
mutation-containing vs. control cells, consistent with the known
repressive function of TRα1 (209 genes in group C). Gene On-
tology (GO) analysis showed that many of these down-regulated
genes relate to DNA-templated transcription, ectoderm and nervous
system development, or cell–cell adhesion via membrane adhesion
molecules (Fig. 3B), with substantial overlap (Fig. 3C). Genes
relating to both transcription and neural development include
bHLH-transcription factors such as NEUROD1, NEUROD4
(MATH3), and NEUROG2, which are involved in normal cere-
bral cortex development (24), as well as LHX2, which is known
to regulate the specification of cortical regional fates (25). The
genes involved in both neural development and cell–cell adhe-
sion are 6 protocadherins (part of the cadherin family), the autism
susceptibility gene NRXN1 (neurexin), and NPTN (neuroplastin),
which has been associated with cortical thickness and intellectual
ability in humans (26, 27).
Thus, our RNA-seq data show that THRA mutations are as-
sociated with the down-regulation of genes involved in neural
development. In addition, the data suggest compromised cell–
cell adhesion in THRA mutation-containing cells, possibly con-
tributing to impaired cortical growth. Notably, within up-regulated
(group B) genes, enrichment for nonneural differentiation fates
was not detected, suggesting that the reduced efficiency of neural
induction seen in THRA mutation-containing cells is not due to
differentiation down nonneural paths.
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Fig. 2. Inefficient cortical induction of THRAmutation-containing iPSCs. (A) Schematic of the in vitro cortical differentiation protocol. (B) TRα1 is expressed in
cycling Ki67+ progenitors as well as postmitotic Tuj1+ neurons derived from control iPSCs. (Scale bars: 50 μm.) (C) Representative pictures showing reduced
progenitor rosette formation and Pax6 expression in THRA mutation-containing cells compared with control cultures at day 15. At least 3 independent
differentiations were performed for 1 clone from each patient. (Scale bars: 50 μm.) (D) Quantification of Pax6 expression within and outside of neural
progenitor cell rosettes in THRA mutant and control cell cultures at day 15 of neural induction. Rosettes were manually delineated based on morphology in
8 or 9 images from 2 or 3 independent inductions for each cell line, and Pax6 expression was measured relative to DAPI (Methods). Error bars indicate SEM.
*P < 0.001, 2-sided Student’s t test comparing a total of nine control and 24 THRA mutant images.
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CD271−CD44− Cortical Progenitor Cells Generate Functional Neurons
In Vitro. To compare neural development from THRA mutation-
containing versus control cortical progenitors while controlling
for differences in induction efficiency, cultures were enriched for
neural stem cells by FACS at day 16 after neural induction.
Based on an established neural stem cell signature (28), the
CD271−CD44− population was isolated and propagated (Fig.
4A). CD271 is expressed in neural crest precursors (29, 30),
which are occasionally observed as a contaminant in control
cortical inductions in vitro and identified based on their char-
acteristic morphology as more prominent in THRA mutant in-
ductions. Negative selection for CD44, a pluripotent stem cell
marker (28), eliminated cells that had failed induction to neural
stem cell fate. Depending on induction efficiency, approximately
50% to 80% of induced THRA mutation-containing cells were
FACS-selected for propagation (Fig. 4A). FACS-enriched cul-
tures expressed PAX6 and the intermediate filament protein
vimentin, both of which are neural progenitor cell markers (Fig.
4A and SI Appendix, Fig. S2F).
Over time, FACS-sorted progenitors gave rise to neurons
expressing the transcription factors TBR1 and CTIP2, expressed
by deep cortical layer neurons (Fig. 4B). Most neurons also
showed punctate vesicular glutamate transporter (VGLUT1) ex-
pression, indicating their glutamatergic identity (Fig. 4B). Overall,
FACS successfully enriched for cortical neural progenitors derived
from THRA mutation-containing iPSCs, which proceeded to
generate cortical excitatory neurons over time in vitro.
To assess neuronal function, 60-d-old THRAmutation-containing
and control cultures were analyzed by single-cell electrophysiology.
The THRA mutation-containing neurons fired action potentials
normally in response to stepwise current injections (Fig. 4C) and
displayed sodium and potassium currents in response to voltage
stimulation (SI Appendix, Fig. S3A). Spontaneous miniature excit-
atory postsynaptic currents were observed in a similar proportion of
THRA mutation-containing and control neurons (SI Appendix, Fig.
S3A). The THRA mutation-containing neurons appeared more
mature than controls, with a greater proportion of cells firing action
potentials (10/11 in FS397 vs. 8/14 in H9; P < 0.1, 2-proportion Z-
test), more action potentials fired per burst (mean, 7.3 ± 2.5 in
FS397 vs. 1.6 ± 1.0 in H9; P < 0.05, Student’s t test), larger mean
peak sodium currents (mean, −398 ± 66 in FS397 vs. −225 ± 48 in
H9; P < 0.05, Student’s t test), and a lower average membrane
potential (−54 ± 2 mV in FS397 vs. −48 ± 3 mV in H9; P = 0.12,
Student’s t test). These differences might represent variations in
individual neuronal properties but could also be due to earlier pro-
duction of neurons in THRA mutation-containing cultures.
By day 50 postinduction, both control and THRA mutation-
containing cells developed spontaneous neuronal network ac-
tivity, visualized by calcium imaging (Fig. 4D and SI Appendix,
Fig. S3B). Spontaneous activity was blocked by the sodium
channel blocker tetrodotoxin and substantially reduced by the
AMPA receptor antagonist CNQX, indicating that a significant
element of the observed spontaneous neuronal activity is medi-
ated by excitatory synaptic transmission (SI Appendix, Fig. S3C).
Compromised Cortical Progenitor Cell Dynamics in THRA Mutation-
Containing Cells. The microencephaly and reduced white matter
tract density seen in patients with RTHα suggest that struc-
tural differences in the cerebral cortex might contribute to their
neurocognitive phenotype. With human cortex comprising col-
umns of clonally related excitatory neurons preferentially synaps-
ing with one another (31), the clonal output of a cortical progenitor
cell is a major contributor to cortical size, architecture, and function.
To determine whether defects in early cortical development could
A
B C
Fig. 3. RNA-seq at day 12 of in vitro cortical induction reveals down-regulation of transcription, neurogenesis, and cell–cell adhesion in THRA mutation-
containing cells. (A) 2D hierarchical clustering of log2(RPKM) values for 3 inductions each from control iPSCs and the 3 patient lines. Colors correspond to
relative expression in each row, from lowest (blue) to highest (red). Inductions cluster by cell line of origin (vertical axis), while genes separate into 4 dif-
ferentially expressed groups (horizontal axis). (B) FDR q values of GO terms enriched among group C genes. (C) GO analysis reveals that genes implicated in
nervous system development that are down-regulated in THRAmutation-containing cells partially overlap with cell–cell adhesion genes (8/42; 19%) and DNA-
templated transcription (10/42; 24%).
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contribute to the neurologic phenotypes of patients, we undertook
single-cell clonal lineage analysis of cortical progenitors, comparing
cell dynamics and clonal output of THRA mutation-containing cells
vs. control cells. A small proportion (≤1%) of THRA mutation-
containing or control cortical progenitor cells, infected with a
GFP-expressing replication-incompetent lentivirus, were mixed
with unlabeled control cultures at day 30 and day 40 after
cortical induction. Their progeny was then traced over time, en-
abling the delineation of cell-intrinsic differences between THRA
mutation-containing and control progenitor cells (Fig. 5A).
The size and composition of clones (2 or more cells) derived
from labeled progenitors were analyzed at 2, 6, and 10 d after
mixing. The majority of labeled cells expressed either Ki67 or the
neuron-specific marker βIII-tubulin, indicating that clones con-
sisted of cycling progenitors and neurons (Fig. 5B). Across the 3
THRA mutation-containing and 3 control cell lines (human iPSC
lines NDC and NAS6 and human embryonic stem cell line H9),
the average size of clones increased progressively over the 10-d
period after labeling (Fig. 5C). Average clone sizes were similar
in control cortical progenitor cells labeled at either day 30 or day
40, whereas the size of THRA mutation-containing clones la-
beled at day 40 was markedly reduced.
Analyzing clone composition, the average number of progenitor
cells per clone (as assessed by Ki67 expression) was increased in
control cultures at day 30 and 40 (Fig. 5C). In THRA mutation-
containing cultures, progenitor cell numbers increased only slightly
at day 30 and decreased at day 40, suggesting a differing pattern of
cell division with earlier cell cycle exit of THRAmutation-containing
progenitors. Thus, depletion of the THRA mutation-containing
progenitor pool leads to premature neuron production and a
decrease in clonal output over time. By live imaging of cells over
a 48-h period, we confirmed that these differences were not due
to altered cell cycle kinetics or increased cell death (SI Appendix,
Fig. S4). Furthermore, the majority of KI67− cells were TUJ1+ in
both control and THRA mutation-containing cell cultures (Fig.
5B); thus, any difference in the proportion of progenitors en-
tering quiescence, if present, is likely negligible.
Premature Cell Cycle Exit of THRAMutation-Containing Cortical Progenitor
Cells. To further quantitate the division pattern of progenitor cells,
fully differentiated clones were distinguished from persisting clones
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Fig. 4. FACS-enriched THRAmutation-containing cortical progenitor cells generate functional neuronal networks. (A) Representative FACS results forWT and THRA
mutation-containing cells at day 18. Immunocytochemistry confirmed the cortical identity of FACS- selected progenitor cells. (Scale bars: 50 μm.) (B) Neurons pro-
duced by FACS-purified progenitor cells expressed the cortical layer-specific transcription factors TBR1 (layer VI) and CTIP2 (layer V), as well as the vesicular glutamate
transporter vGlut1, at day 40. (Scale bars: 50 μm.) (C) Representative traces showing action potential firing in response to stepwise current injection in THRA
mutation-containing and control neurons. Numbers indicate the proportion of cells that fired action potentials. (D) Calcium indicator Oregon Green BAPTAwas used
as a proxy for action potential firing to measure spontaneous neuronal activity. Fluorescence images show control and THRA mutant cultures after loading. Heat
maps highlight different levels of activity across the cultures. Total calcium activity across the field of view, ACa, was quantified based on 3 to 6 videos from each cell
line (403X and FS382, n = 6 samples from 2 independent inductions; all others, n = 3 samples from 1 induction; *P < 0.05, Student’s t test). Error bars indicate SEM.
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containing at least 1 progenitor cell (Fig. 6A). The proportion of
persisting clones decreased more rapidly in THRA mutation-
containing than control cultures (Fig. 6A). At the same time, the
average size of persisting clones increased near-exponentially in con-
trols but more linearly in THRA mutant cells at day 40 (Fig. 6B),
suggesting that a higher proportion of control progenitor cells are
self-renewing symmetrically, whereas THRA mutation-containing
progenitor cells have transitioned to a more asymmetric, neurogenic
division pattern.
To test this, we used a computational model of human cortical
development in which self-renewing radial glia (RGs) produce in-
termediate progenitor cells (IPCs), which generate neurons through
asymmetric or terminal divisions (SI Appendix, Supplementary
Methods and Fig. S5). Based on the findings of a recent in vivo
genetic labeling study of cortical neurogenesis in mouse, we pre-
sumed that RGs transit from a phase of symmetrical proliferation
to a neurogenic phase, in which they divide asymmetrically to give
rise to IPCs with variable but limited neurogenic potential (32). We
found that this model could largely account for differences in the
clonal behavior of THRA mutation-containing vs. control cells, in-
cluding the distribution of clone size and composition, under the
single assumption that THRA mutation-containing RGs differenti-
ated into IPCs at a higher rate compared with control RGs (Fig. 6 B
and C). Therefore, the clonal lineage data and the computational
model together demonstrate that THRA mutation-containing pro-
genitor cells switch to neurogenesis earlier than control cells, which
continue proliferating.
During human neurogenesis, the deepest neuronal layers of
the cerebral cortex emerge first, whereas neurons of the upper
layers appear subsequently and migrate away from the pro-
genitor cell zone to their final positions. Therefore, expression of
TBR1, which is high in layer VI neurons in the developing cortex,
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is thought to precede expression of CTIP2, which is low in layer
VI neurons but high in layer V neurons (33). Quantification of
CTIP2 and TBR1 expression in THRA mutation-containing and
control cells at day 40 showed significantly more TBR1+ and
CTIP2+ cells in mutant compared with control cell cultures,
providing independent evidence for premature neuronal differ-
entiation of THRA mutation-containing progenitor cells (SI
Appendix, Fig. S6).
Cell Polarity and Rosette Self-Assembly Defects in THRA Mutation-
Containing Cortical Progenitor Cells. Previous studies have shown
that cortical progenitor cell polarity and attachment at the ven-
tricular surface maintain progenitor identity and proliferation in
the mouse cortex (34), consistent with foregoing our gene ex-
pression data. The functional units of corticogenesis in the in
vitro system are rosette-like arrangements of progenitor cells,
which self-assemble and recreate aspects of the in vivo niche
(22). We observed that following dissociation, THRA mutation-
containing progenitors self-organized into rosettes less readily
than controls. To quantify the efficiency of rosette formation,
progenitor cells were plated at a defined density onto micro-
patterned chips that only allow cell adhesion in circular areas of
different diameters (Fig. 7A).
In control lines, rosettes formed efficiently within 48 h after
plating, with areas of 140 μm diameter predominantly hosting a
single rosette (Fig. 7B). The organization of cell types within rosettes
showed clear apical-basal polarity (Fig. 7C). In contrast, rosette
formation was substantially impaired in THRA mutation-containing
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cell cultures (Fig. 7D). Treatment of control cultures with the
competitive TR antagonist 1-850 (35) decreased rosette forma-
tion efficiency and proliferation, indicating that aberrant TH
signaling likely contributes to impaired rosette formation (SI Ap-
pendix, Fig. S7A).
The mechanisms underlying neural rosette formation in vitro
are largely enigmatic (36). Live imaging of control cultures for up
to 72 h after plating found no evidence for directional movement
of cells, suggesting that cells do not respond to chemotactic signals
(SI Appendix, Fig. S7B). To test which factors are required for
rosette formation, we developed a computational model in which
cells move randomly and form attachments at their apical ends
when in close proximity. Both the number of rosettes and the dis-
tribution of rosette centers observed in vitro were statistically
reproduced in silico, indicating that migration and apical attach-
ment are sufficient for rosette formation (SI Appendix, Fig. S7C). As
migration defects were not apparent from the live imaging data (SI
Appendix, Fig. S7B), impaired apical attachments may be limiting
rosette formation efficiency in THRA mutation-containing cultures.
In support of this notion, N-cadherin was highly localized to the
apical end of progenitor cells in control rosettes but expressed
along the cell membrane in THRA mutation-containing cells,
suggesting impaired adherens junction formation (Fig. 7 D and E),
consistent with the down-regulation of protocadherins observed
on RNA-seq. Apical expression of the polarity complex protein
PKCζ and the centrosome-associated γ-tubulin was observed in
control progenitor cells but not in THRA mutation-containing
cells (SI Appendix, Fig. S7D). Thus, defects in progenitor cell po-
larity and spatial organization may contribute to their premature
cell cycle exit.
Discussion
Consistent with the known critical role of TH in brain develop-
ment, we have documented neurocognitive deficits (e.g., reduced
nonverbal IQ, motor incoordination, impaired visual motor in-
tegration) in patients with RTHα, with some deficits (e.g., motor
incoordination, poor finger/hand dexterity) resembling conse-
quences of untreated congenital hypothyroidism. Structural ab-
normalities include reduction in cerebellar volume, cortical
microencephaly in adult cases, and decreased white matter tract
density. The neurocognitive, structural, and functional deficits
observed in patients with RTHα suggest abnormalities in several
brain regions, including the axis from the cerebellum to the
neostriatum and the cerebral cortex. Here we focused on the
effects of mutant TRα1 on cerebral cortex development and
function, using cortical neural progenitor cells derived from
THRAmutation-containing iPSCs from these patients. While our
experimental model effectively recapitulates defined aspects
of corticogenesis in vitro, it does not capture other brain de-
velopmental processes, such as myelination and cerebellar de-
velopment, that may also be impaired in patients and should be
elucidated in future studies.
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Our cortical differentiation protocol revealed that THRAmutation-
containing cortical progenitor cells differentiate prematurely in
vitro, with attendant depletion of the progenitor cell pool reducing
clonal output, which in vivo would result in microencephaly.
Quantitative analysis of lineage tracing data confirmed that the
fate choices of THRA mutation-containing cortical progenitor
cells are biased toward neuronal differentiation as opposed to the
continued self-renewal observed in control cells. As single-labeled
THRA mutation-containing progenitor cells were studied in WT
background cultures, such alterations in clonal dynamics likely
reflect distinct cell-autonomous fate behaviors.
RNA-seq of early cortical progenitor cells indicated down-
regulated expression of genes involved in cell polarity or adher-
ence in THRA mutation-containing cells. These included several
protocadherins whose cellular functions are not fully understood
but may act as adhesion molecules on their own or in association
with other cadherins (37). THRA mutation-containing cortical
progenitor cells also showed disordered expression of N-cadherin,
a well-described classical cadherin, and defective self-organization
into rosettes on micropatterned chips, which may be explained by
reduced apical cell–cell adhesion based on our computational
model. Taken together, these results indicate that apical adherens
junction formation is impaired in THRA mutation-containing
cortical progenitor cells. In rodent studies, ventricular attach-
ment through adherens junctions is required for apical-basal po-
larity, spatial organization, and self-renewal of cortical RGs (34,
38, 39), and there is emerging evidence indicating that protocadherins
play a role in these processes (40, 41).
In the developing cerebral cortex, neural progenitor cell in-
teractions through adherens junctions have been shown to consti-
tute a self-supportive niche maintaining progenitor cell proliferation
and inhibiting differentiation (42). Thus, defects in cell polarity and
attachment to neighboring stem cells may mediate the premature
cell cycle exit observed in THRA mutation-containing cortical
progenitor cells. Our findings also suggest that some cell-intrinsic
consequences of mutant TRα1 dysfunction may become appar-
ent only through interactions with the local niche. We note,
however, that our in vitro cortical differentiation protocol gen-
erates a reduced model of the actual human cortex, lacking, for
example, vasculature and surrounding supportive tissues, as well
as nonneuronal cells, such as microglia. Neural progenitor cells
in vivo reside in a distinct 3D architecture with axial patterning
signals and neurophysiological activity not replicated in vitro.
Thus, our in vitro results on the structure and organization of
neural progenitor cell rosettes might not directly translate to the
in vivo situation. Future studies may establish the functional
hierarchy of determinants of cortical progenitor cell identity in
vivo, to further delineate the mechanisms through which mutant
TRα1 affects neurogenesis. It will also be important in future
studies to validate the modeling presented here that predicts a
change in intermediate progenitor cell dynamics.
Overall, we suggest that abnormal proliferation and adhesion
of THRA mutation-containing cortical neural progenitors forms
the basis, at least in part, of structural and functional changes
culminating in neurocognitive deficits seen in patients with RTHα.
We note that our lineage-tracing experiments and RNA-seq data
cannot resolve whether the observed differences in gene expres-
sion and cell fate behavior are due to transcriptional changes
within a comparable population of neural progenitor cells, changes
in the cellular composition of the progenitor cell populations, or a
combination of these 2 possibilities. As our understanding of hu-
man corticogenesis is still evolving, with the cell states and cell
types involved not yet definitively identified, this distinction is at
present semantic and does not affect the conclusions of our study.
Reduced cortical progenitor output and impaired cortical ar-
chitecture have been observed in human patients and mouse
models of several other neurodevelopmental disorders, including
Down syndrome, schizophrenia, and autism spectrum disorders
(43–46). A number of genes differentially expressed in THRA
mutation-containing cells, including the cell surface dystroglycan
receptor NRXN1 (neurexin) and the transmembrane protein
NPTN (neuroplastin), have also been implicated in other
neurodevelopmental disorders (26, 27). Since normal cortical
progenitor self-renewal requires the orchestration of a range of
cell-intrinsic and environmental factors, including transcription
factors determining cortical stem cell identity and genes regulating
cell attachment, proliferation, and movement, as well as cytoskeletal
organization and polarity (34), a range of gene defects may converge
onto similar abnormal neurodevelopmental phenotypes. Specifically,
our observations suggest that impaired cell adhesion, leading to
defective cortical size and architecture, may ultimately result in
neurocognitive deficits across a range of genetic disorders.
In addition to mouse models, novel human iPSC-derived in vitro
systems are being increasingly used to study neurodevelopmental
conditions, hitherto focusing on neuronal maturation and network
function (47–51). Extending these approaches, this study describes
a method of assessing the proliferative potential and fate of neural
stem cells in vitro. Through quantitative analysis of lineage tracing
data, even minor differences in clonal dynamics can be resolved. In
addition, we have developed a quantitative assay for the self-
organizing capacity of neural stem cells. Together, these ap-
proaches provide an experimental platform to investigate the
function of cortical progenitor cells with differing genetic back-
grounds, study neural progenitor cell dynamics during normal
and pathological development, and ultimately screen for agents
to ameliorate defective neurogenesis.
Materials and Methods
Themethodology used in this study is described inmore detail in SI Appendix.
Neuroimaging. Whole-brain MRI, DTI, and proton MRS were performed at
Great Ormond Street Hospital, London and compared with data obtained
from healthy age-matched controls. All clinical investigations, including
neuroimaging and derivation of iPSCs, were undertaken as part of a protocol
approved by our Research Ethics Committee (Cambridgeshire; LREC 98/154) or
were clinically indicated andwere performedwith previous written informed
consent of patients and/or parents.
Neural Differentiation of iPSCs. Neural induction of human control PSCs and
THRA mutant iPSCs was performed as described previously (21). For FACS
sorting, 106 cells per sample were collected and stained with fluorochrome-
conjugated antibodies. Total RNA from cortical cultures was isolated using
TRIzol (Sigma-Aldrich), and semiquantitative RT-PCR was performed using
primers against FOXG1, PAX6, and GAPDH. For Western blot analysis, protein
was extracted from overnight-frozen cell pellets, and the insoluble fraction
was removed by centrifugation. Band intensity was measured using Image
Studio software (Li-COR) and normalized to β-actin. Immunofluorescence
staining was performed following fixation with 4% paraformaldehyde.
Electrophysiology and Calcium Imaging. For electrophysiological recordings,
cortical neurons were incubated with artificial cerebral spinal fluid and
subjected to step depolarizations or stepwise current injections. Recordings
were made using a Multiclamp 700 A amplifier (Molecular Devices). For
calcium imaging, cells were incubated with calcium indicator Oregon Green
488 BAPTA, and calcium activity was recorded on a Deltavision fluorescence
microscope with an EMCCD camera (Applied Precision).
Clonal Lineage Analysis. For clonal lineage analysis, third-generation replication-
incompetent lentivirus was produced by calcium phosphate transfection of
HEK293T cells, using pBOP-GFP plasmids combined with packaging plasmids
pRSV-Rev, pMDLg/pRRE, and pMD2.G. Cortical progenitor cells were infected at
high titer before isolation of the CD271−CD44− population by FACS. At day
30 and day 40, sorted progenitors were mixed with unlabeled control cultures.
Thesemixed cultures were fixed and immunostained at 2, 6, and 10 d after plating.
Micropattern Chip Cultures. For micropattern chip cultures, 106 cells were
plated onto laminin-coated CYTOOchips and cultured for 1 to 7 d. For live
imaging, tissue culture dishes containing cells in N2B27 medium were im-
aged in a BioStation CT (Nikon) at 37 °C with 7% CO2.
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RNA-Seq. For RNA-seq, total RNA was extracted from 3 control lines and 3
THRA mutant lines at day 12 of in vitro cortical induction. Libraries were
prepared using the Illumina TruSeq Stranded Total RNA sample preparation
kit and single-end sequenced on an Illumina HiSeq 1500 system. Gene ex-
pression profiles were clustered using GeneE software, based on Pearson’s
correlation. GO analysis was performed using the PANTHER database
(www.panther.org).
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